Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25
Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day’s highlights from X/Twitter.
”SABCS23 Day 1 Highlights Community Oncology:
2. EMERALD
3. TDxD
4. Tumor Agnostic landscape
5. Post CDK4/6i HR+
![](https://oncodaily.com/pub/uploads/2023/12/f8abbbd8e89b46709e8bfea66082058d-800x263.jpg)
– Pending OS,
– 400mg BID, 4days on/3days off.
![](https://oncodaily.com/pub/uploads/2023/12/d551bc2a727b4f37b06dccedef0b5f9c-800x373.jpg)
most Benefit CDK4/6i >12mos,
– AE: musculoskeletal pain, nausea,
increased cholesterol.
![](https://oncodaily.com/pub/uploads/2023/12/8ea597d84989490fbb584968a1526008-800x445.jpg)
– mFU 32mos, OS 23.9mos vs 17.6 mos (in Hr+, HR: 0.69),
– OS 22.9mos vs 16.8mos (in All Pts, HR: 0.69).
For the more information click here.
4. Tumor Agnostic landscape: 2017-22
– Pembro + Dostar in MSI-H. Pembro in High TMB,
– Larotrectinib + Entrectinib in NTRK,
– Dabrafenib/Trametinib in BRAF V600E,
– Selpercatinib in RET fusion.
For the more information click here.
5. What to do post CDK4/6i: phenomenal session!
– PARPi, AKT pathway, ESR1 or ADCs, everolimus and chemo are potential options. Switch CDK4/6i Rx might be an option,
– Abigail Johnston, one of the most moving talks I have EVER heard!”
Source: Oncology Brothers/X